Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing...
-
Upload
gerard-harper -
Category
Documents
-
view
220 -
download
0
description
Transcript of Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing...
![Page 1: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/1.jpg)
Endometrial CancerCPGON Audit
![Page 2: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/2.jpg)
Background• Formulating standard management
pathways• Assessing compliance with existing
pathways• Understanding areas of similarity and
areas of variation
![Page 3: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/3.jpg)
Specific Questions• Endometrial cancer 2011-2013 inclusive• Caseload and waiting times• Tumour grade: how it affects management and
outcome• Move toward laparoscopic surgery• Imaging• Survival• Trial recruitment
![Page 4: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/4.jpg)
Data collection• Access Database with specific forms• Sent to 5 hospitals: Taunton, Exeter, Yeovil,
Torbay, NDDH• Returns received from all except NDDH• Data presented reflect data entered• Significant influence of missing data (esp on
Grade data)
![Page 5: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/5.jpg)
Data analysis
• Taunton/Yeovil and Exeter/Torbay analysed separately
• Exeter data include NDDH cases who had hysterectomy in Exeter, but diagnostic data are missing
![Page 6: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/6.jpg)
Cases: Exeter/Torbay/NDDHHysterectomy?
Source site No Yes Total
Exeter 15 212 227
NDDH 7 43 50
Other 2 2
Plymouth 1 1
Private 3 3
Torbay 15 104 119
Grand Total 38 364 402
![Page 7: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/7.jpg)
Cases: Taunton/YeovilHysterectomy?
Source site No Yes Total
Exeter 1 1
Other 3 3
Private 3 3
Taunton 17 117 134
Yeovil 4 90 94
Grand Total 21 214 235
![Page 8: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/8.jpg)
Where hysterectomies done
• Counts of cases by location of surgery and according to site of diagnosis
![Page 9: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/9.jpg)
Exeter
Torbay
Taunton (from
Yeovil)
0 20 40 60 80 100 120 140 160 180 200
182
115
62
49
37
24
Hysterectomies 2011-2013
![Page 10: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/10.jpg)
Waits for Hysterectomy• Reported as mean in days• Includes some long waits. Very long
waits (>100d) excluded if biopsy field blank
• Assumed to be cases where cancer not suspected or known
![Page 11: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/11.jpg)
Taunton
NDDH
Torbay
Taunton(fromYeovil)
Exeter(fromTorbay)
Exeter
Yeovil
0 5 10 15 20 25 30 35 40 45
27
28
32
33
39
40
40
Wait (d)
![Page 12: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/12.jpg)
Taunton Exeter Yeovil Torbay0
10
20
30
40
50
60
70
80
90
71
56
33
0
67
55
71
6
8376 75
56
% Laparoscopic
201120122013
![Page 13: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/13.jpg)
Laparoscopic• Continues to rise• Need clarity on what the expected
figure should be• Exeter and Taunton consensus is that
transverse laparotomy is very rarely indicated
![Page 14: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/14.jpg)
Taunton Exeter Yeovil Torbay0
10
20
30
40
50
60
70
80
90
100
1318
42
100
1421
29
94
2 4
17
44
%Transverse laparotomy
201120122013
![Page 15: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/15.jpg)
Influence of Tumour Grade• Several issues:
–What grade should trigger referral to centre
– Proportion of cases undergraded and therefore underinvestigated and under-referred
– Does biopsy grade predict need for adjuvant therapy?
![Page 16: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/16.jpg)
Current Practice
• Yeovil/Taunton: – G2 and 3 referred to Centre– G2 called HG (according to data submitted)– G2 and G3 have cross sectional imaging
• Exeter/Torbay/NDDH:– G3 only referred to centre– G2 called LG– Only G3 have cross-sectional imaging
![Page 17: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/17.jpg)
Grade analysis• Problem of missing data: each case
needs two grade data fields entered to contribute (biopsy and final)
• How to calculate upward grade shift• Decision to use denominator of grades
able to shift (ie exclude G3)
![Page 18: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/18.jpg)
Exeter Torbay Taunton Yeovil0
10
20
30
40
50
60
70
80
90
70
8076 78
% Cases where Grade did NOT change at hysterectomy
![Page 19: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/19.jpg)
Exeter Torbay Taunton Yeovil0
2
4
6
8
10
12
14
1211
5
7
% Of G1/2 shifted to G3 at hys-terectomy
![Page 20: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/20.jpg)
Exeter Torbay Taunton Yeovil0
10
20
30
40
50
60
70
80
90
100
% Cases imaged
G1G2G3
![Page 21: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/21.jpg)
Exeter Torbay Taunton Yeovil0
2
4
6
8
10
12
14
16
18
% Final G3 not imaged
![Page 22: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/22.jpg)
TY/G1 TY/G2 TY/G3 ET/G1 ET/G2 ET/G30%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
107 52
26
101 119
102
0 2
8
4 430
DeadAlive
Survival by Grade
![Page 23: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/23.jpg)
Survival• Kaplan Meier for Exeter/Torbay/NDDH
cases• Highly significant G3 worse than G1
and G2, which were the same• Regret no similar plot for
Taunton/Yeovil
![Page 24: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/24.jpg)
![Page 25: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/25.jpg)
Adjuvant Radiotherapy• Again a missing data issue• How does biopsy grade predict
likelihood of adjuvant radiotherapy after hysterectomy?
• Hyperplasia = cases where biopsy showed hyperplasia but hysterectomy revealed cancer
![Page 26: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/26.jpg)
Hyperplasia G1 G2 G30%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
40 51 42
29
6 11 6
19
8 12 1432
Adjuvant Treatment Exeter/Torbay
EBRTBrachyNone
![Page 27: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/27.jpg)
Hyperplasia G1 G2 G30%
10%20%30%40%
50%60%70%80%90%
100%
20 49
14
3
310
10
8
3 1011
14
Adjuvant treatment Taunton/Yeovil
EBRTBrachyNone
![Page 28: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/28.jpg)
Grade conclusions• Survival data clear that G1 and 2 are
separate from G3• However, in Yeovil, G2 referral means:– Quicker operation– Accurately selects cases who need
adjuvant treatment
![Page 29: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/29.jpg)
188
75
43
3713 Stage in Exeter/Torbay
n=402
IA IB IIIII IV
![Page 30: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/30.jpg)
IA IB II III IV Unknown0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
178 70 40
24
6
31
10 5 3
13
8
15
Survival by FIGO stage Exeter/Torbay
DeadAlive
![Page 31: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/31.jpg)
![Page 32: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/32.jpg)
Clear c
ell
Endo
metrioi
dMMMT
Sarco
maSe
rous
0%10%20%30%40%50%60%70%80%90%
100%
10252
5 738
214
4 411
DeadAlive
Survival by Morphology
![Page 33: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/33.jpg)
Exeter Torbay Taunton Yeovil0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
11 017 8
216 119117 86
Trial Recruitment
NoYes
![Page 34: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/34.jpg)
Exeter Torbay Taunton Yeovil0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
25 9 17 8
202 110 117 86
Chemotherapy
NoYes
![Page 35: Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.](https://reader036.fdocuments.in/reader036/viewer/2022062412/5a4d1b097f8b9ab0599899bc/html5/thumbnails/35.jpg)
Conclusions• Variation within the Network (Grade triage)• Guidelines will need to reflect this, or
practice change• Patients do well and results in keeping with
published literature• We can do good audits together!!